Expert Interview
Looking into the potential of Tremfya (guselkumab) in patients with inflammatory bowel disease and moderate to severe active ulcerative colitis
Ticker(s): JNJInstitution: NYU Langone Long Island
- Medical Director for the Inflammatory Bowel Diseases (IBD) Program at NYU Langone Long Island
- Practice encompasses all facets of general gastroenterology including gastroesophageal reflux disease (GERD), peptic ulcer disease, chronic constipation, ulcerative colitis and irritable bowel syndrome (IBS), with additional expertise in inflammatory bowel diseases
- Co-authored several studies in inflammatory bowel disease
- Manages 150 patients with ulcerative colitis and prescribes Zeposia to 5 patients
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
